The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Challenges and Future Trends in the Treatment of Psoriasis
Open accessAbstract
Psoriasis is a chronic inflammatory skin disorder, and current treatments include topical therapies, phototherapy, systemic immune modulators, and biologics, aiming to alleviate symptoms and improve quality of life. However, challenges persist, such as adverse effects, treatment resistance, high costs, and variability in response among individuals. The future of psoriasis treatment shows promising emerging trends. New biologic agents targeting novel pathways, such as interleukin 23 inhibitors like mirikizumab, offer enhanced efficacy. Small molecule inhibitors like RORγt inhibitors and ROCK2 inhibitors provide additional treatment options. Combination therapies, including biologics with methotrexate, may improve treatment response. Advancements in topical treatments utilizing microneedles and nanoparticle-based carriers can enhance drug delivery and improve therapeutic outcomes. Biomarkers and multi-omics technologies hold potential for personalized treatment approaches, thus aiding in diagnosis, predicting treatment response, and guiding therapeutic decisions. Collaboration among researchers, clinicians, and industry stakeholders is crucial to translating these scientific breakthroughs into clinical practice. By addressing current challenges and exploring these promising trends, we can optimize psoriasis management and improve the lives of those affected by this chronic condition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prausnitz, M. R., & Langer, R. (2008) · Nature Biotechnology · doi:10.1038/nbt.1504 · Cited by 3,517
Griffiths, C. E. M., Armstrong, A. W., Gudjonsson, J. E., & Barker, J. N. W. N. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32549-6 · Cited by 2,383
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review
Armstrong, A. W., & Read, C. (2020) · JAMA · doi:10.1001/jama.2020.4006 · Cited by 2,335
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Menter, A., Strober, B. E., Kaplan, D. H., Kivelevitch, D., Prater, E. F., Stoff, B., Armstrong, A. W., Connor, C., Cordoro, K. M., Davis, D. M. R., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.057 · Cited by 969
Definition of treatment goals for moderate to severe psoriasis: a European consensus
Mrowietz, U., Kragballe, K., Reich, K., Spuls, P., Griffiths, C. E. M., Nast, A., Franke, J., Antoniou, C., Arenberger, P., Balieva, F., et al. (2011) · Archives of Dermatological Research · doi:10.1007/s00403-010-1080-1 · Cited by 898
Kalb, R. E., Fiorentino, D. F., Lebwohl, M. G., Toole, J., Poulin, Y., Cohen, A. D., Goyal, K., Fakharzadeh, S., Calabro, S., Chevrier, M., et al. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.0718 · Cited by 373
Psoriasis: Which therapy for which patient
Kaushik, S. B., & Lebwohl, M. G. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.06.057 · Cited by 368
Elmets, C. A., Korman, N. J., Prater, E. F., Wong, E. B., Rupani, R. N., Kivelevitch, D., Armstrong, A. W., Connor, C., Cordoro, K. M., Davis, D. M. R., et al. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.07.087 · Cited by 352
Menter, A., Gelfand, J. M., Connor, C., Armstrong, A. W., Cordoro, K. M., Davis, D. M. R., Elewski, B. E., Gordon, K. B., Gottlieb, A. B., Kaplan, D. H., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.02.044 · Cited by 346
Abdelbary, A. A., & AbouGhaly, M. H. H. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.03.020 · Cited by 302
Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis
Armstrong, A. W., Puig, L., Joshi, A., Skup, M., Williams, D., Li, J., Betts, K. A., & Augustin, M. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.4029 · Cited by 294
Egeberg, A., Ottosen, M. B., Gniadecki, R., Broesby-Olsen, S., Dam, T. N., Bryld, L. E., Rasmussen, M. K., & Skov, L. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16102 · Cited by 284
Microneedle-mediated transdermal drug delivery for treating diverse skin diseases
Yang, D., Chen, M., Sun, Y., Jin, Y., Lu, C., Pan, X., Quan, G., & Wu, C. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.12.004 · Cited by 259
Carter, P., Narasimhan, B., & Wang, Q. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.11.032 · Cited by 247
Psoriasis and Treatment: Past, Present and Future Aspects
Reid, C., & Griffiths, C. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3386 · Cited by 221
Wan, T., Pan, Q., & Ping, Y. (2021) · Science Advances · doi:10.1126/sciadv.abe2888 · Cited by 220
Blauvelt, A., Leonardi, C. L., Gooderham, M., Papp, K. A., Philipp, S., Wu, J. J., Igarashi, A., Flack, M., Geng, Z., Wu, T., et al. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.0723 · Cited by 217
Generalized pustular psoriasis: a review and update on treatment
Hoegler, K. M., John, A. M., Handler, M. Z., & Schwartz, R. A. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14949 · Cited by 204
Pandya, V. B., Kumar, S., Sachchidanand, Sharma, R. K., & Desai, R. C. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00588 · Cited by 150
The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis
Madonna, S., Girolomoni, G., Dinarello, C. A., & Albanesi, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133318 · Cited by 148
IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis
Hussain, S., Berki, D. M., Choon, S. E., Irvine, A. D., Allen, M. H., Aróstegui, J. I., Chaves, A., Duckworth, M., Irvine, A. D., Mockenhaupt, M., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.09.043 · Cited by 146
Hazlewood, G. S., Barnabe, C. C. M., TOMLINSON, G. A., Marshall, D. A., Devoe, D. J. A., & Bombardier, C. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010227.pub2 · Cited by 145
Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments
Misiak-Gałązka, M., Zozula, J., & Rudnicka, L. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00503-5 · Cited by 143
The role of vitamin D in psoriasis: a review
Soleymani, T., Hung, T., & Soung, J. (2015) · International Journal of Dermatology · doi:10.1111/ijd.12790 · Cited by 141
Bessar, H. A., Venditti, I., Benassi, L., Vaschieri, C., Azzoni, P., Pellacani, G., Magnoni, C., Botti, E., Casagrande, V., Federici, M., et al. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.01.021 · Cited by 141
Krueger, J. G., McInnes, I. B., & Blauvelt, A. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.06.869 · Cited by 135
Reich, K., Leonardi, C. L., Langley, R. G. B., Warren, R. B., Bachelez, H., Romiti, R., Ohtsuki, M., Xu, W., Acharya, N. V., Solotkin, K. C., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.10.027 · Cited by 99
Zanin‐Zhorov, A., Weiss, J. M., Trzeciak, A. J., Chen, W., Zhang, J., Nyuydzefe, M. S., Arencibia, C., Polimera, S., Schueller, O. J. A., Fuentes‐Duculan, J., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1602142 · Cited by 98
Papp, K. A., Leonardi, C., Blauvelt, A., Reich, K., Korman, N., Ohtsuki, M., Paul, C. F., Ball, S. G., Cameron, G. S., Erickson, J., et al. (2017) · British Journal of Dermatology · doi:10.1111/bjd.16050 · Cited by 97
Conti, P., Pregliasco, F. E., Bellomo, R. G., Gallenga, C. E., Caraffa, A., Kritas, S. K., Lauritano, D., & Ronconi, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158076 · Cited by 88
Brodalumab in psoriasis: evidence to date and clinical potential
Foulkes, A., & Warren, R. B. (2019) · Drugs in Context · doi:10.7573/dic.212570 · Cited by 81
Biomarkers of disease progression in people with psoriasis: a scoping review
Ramessur, R., Corbett, M. S., Marshall, D. C., Acencio, M. L., Barbosa, I. A., Dand, N., Meglio, P. D., Haddad, S., Jensen, A. H. M., Koopmann, W., et al. (2022) · British Journal of Dermatology · doi:10.1111/bjd.21627 · Cited by 81
Tang, L., Yang, X. T., Liang, Y., Xie, H., Dai, Z., & Zheng, G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01210 · Cited by 77
Small Molecule IL-36γ Antagonist as a Novel Therapeutic Approach for Plaque Psoriasis
Todorović, V., Su, Z., Putman, C. B., Kakavas, S. J., Salte, K. M., McDonald, H. A., Wetter, J. B., Paulsboe, S. E., Sun, Q., Gerstein, C., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-45626-w · Cited by 74
Kimball, A. B., Rothman, K. J., Kricorian, G., Pariser, D. M., Yamauchi, P. S., Menter, A., Teller, C. F., Aras, G. A., Accortt, N. A., Hooper, M. M., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.08.050 · Cited by 73
Zhang, L., Guo, L., Wang, L., & Jiang, X. L. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18263 · Cited by 61
Poulin, Y. P., & Thérien, G. (2010) · Journal of Cutaneous Medicine and Surgery · doi:10.2310/7750.2009.09007 · Cited by 59
Thomas, L., Azad, J., & Takwale, A. (2020) · Clinical and Experimental Dermatology · doi:10.1111/ced.14314 · Cited by 50
Menter, A., Thaçi, D., Wu, J. J., Abramovits, W., Kerdel, F. A., Arikan, D., Guo, D., Ganguli, A. X., Bereswill, M., Camez, A. A., et al. (2017) · Dermatology and Therapy · doi:10.1007/s13555-017-0198-x · Cited by 49
Lambert, J., Segaert, S., Ghislain, P., Hillary, T., Nikkels, A., Willaert, F., Lambert, J. L. W., & Speeckaert, R. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16684 · Cited by 47
Özcan, A., Şahin, D., Impellizzieri, D., Nguyen, T. T., Hafner, J., Yawalkar, N., Kurzbach, D., Tan, G., Akdiş, C. A., Nilsson, J., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.09.018 · Cited by 46
Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway
Maul, J., Anzengruber, F., Conrad, C., Cozzio, A., Häusermann, P., Jalili, A., Kolios, A. G. A., Laffitte, E., Lapointe, A.-K., Mainetti, C., et al. (2021) · Dermatology · doi:10.1159/000512930 · Cited by 46
The promise and challenges of cell therapy for psoriasis*
Lwin, S. M., Snowden, J. A., & Griffiths, C. E. M. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20517 · Cited by 46
Genital Psoriasis: Impact on Quality of Life and Treatment Options
Kelly, Á., & Ryan, C. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00447-5 · Cited by 42
Gomez, C. B., Muangnoi, C., Sorasitthiyanukarn, F. N., Wongpiyabovorn, J., Rojsitthisak, P., & Rojsitthisak, P. (2019) · Molecules · doi:10.3390/molecules24071388 · Cited by 40
Shores, L. S., Kelly, S. H., Hainline, K. M., Suwanpradid, J., MacLeod, A. S., & Collier, J. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01855 · Cited by 38
Brodalumab for the treatment of plaque psoriasis: up-to-date
Beck, K. M., & Koo, J. Y. M. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1579794 · Cited by 36
Amiri, D., Schwarz, C., Gether, L., & Skov, L. (2023) · Acta Dermato Venereologica · doi:10.2340/actadv.v103.6525 · Cited by 34
Soluble biomarkers for diagnosis, monitoring, and therapeutic response assessment in psoriasis
Pourani, M. R., Abdollahimajd, F., Zargari, O., & Shahidi‐Dadras, M. (2021) · Journal of Dermatological Treatment · doi:10.1080/09546634.2021.1966357 · Cited by 33
Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic Review
Gyldenløve, M., Alinaghi, F., Zachariae, C. O. C., Skov, L., & Egeberg, A. (2022) · American Journal of Clinical Dermatology · doi:10.1007/s40257-022-00703-1 · Cited by 24
Secukinumab (AIN457) for the treatment of psoriasis
López‐Ferrer, A., Vilarrasa, E., & Puig, L. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.1095092 · Cited by 23
Hsieh, T., & Tsai, T. (2023) · Dermatology and Therapy · doi:10.1007/s13555-023-00903-5 · Cited by 23
Recent Advances in Psoriasis Therapy: Trends and Future Prospects
Singh, A. P., & Easwari, T. S. (2021) · Current Drug Targets · doi:10.2174/1389450122666210118103455 · Cited by 21
Spesolimab in the treatment of generalized pustular psoriasis: a critically appraised research paper
Ali, F., Smith, C. H., & Mahil, S. K. (2022) · British Journal of Dermatology · doi:10.1093/bjd/ljac049 · Cited by 4
308 nm-Excimerlaser zur Therapie von Psoriasis und entzündlichen Hauterkrankungen
Fritz, K., & Sălăvăstru, C. (2018) · hautnah · doi:10.1007/s12326-018-0279-3 · Cited by 2
Cited by
The M2 Macrophages Importance Role in Psoriasis
Alshihmani, A. H. H., Mahmoudi, M., Kheder, R. K., Fadaee, A., & Esmaeili, S. (2025) · Immunity, Inflammation and Disease · doi:10.1002/iid3.70211 · Cited by 16
Metadata
- Authors
- Lee, H.-J., & Kim, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-08-28
- Volume
- 24
- Issue
- 17
- Pages
- 13313
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4386221007
- Cited by
- 315
- References
- 55
- FWCI
- 27.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.